Alzheimer's disease—why insulin is a new suspect

June 6, 2018 by Christian Holscher, The Conversation
Credit: Naeblys/Shutterstock.com

Johnson and Johnson recently announced that it was halting a clinical trial for a new Alzheimer's drug after safety issues emerged. This latest failure adds to the dozens of large, costly clinical trials that have shown no effect in treating this devastating disease.

The growing list of failures should give us pause for thought – have we got the causes of Alzheimer's all wrong?

In the first analysis of the disease, the German physician, Alois Alzheimer, noted odd changes in the of a patient who died of the condition. Alzheimer identified two kinds of protein aggregates that are not found in younger brains: plaques that are found between and tangles that are found inside brain cells.

Later research identified the proteins that made up the plaques as amyloid and those that form the tangles as tau. What these structures actually do is still under debate.

Unheeded warning

Alzheimer advised scientists not to jump to the conclusion that these proteins caused the disease. Unfortunately, his caution was ignored, and over the years it has become gospel that the build up of these proteins causes Alzheimer's disease.

One problem is that it's not possible to test, in a scientific experiment, if this theory is correct. Only in recent years has technology been developed that can test what these proteins do, and it is clearly not what scientists previously assumed. For example, genetically engineered mice that accumulate human amyloid in their brains show only mild impairment. But the pharmaceutical industry made up its mind a long time ago that amyloid is the culprit, and this has been the target for Alzheimer's drugs ever since.

The aim of these drugs is to reduce the levels of amyloid in the brain, either by slowing down the formation of amyloid or by removing it from the brain. Both approaches have been tested many times now using different techniques and types. None of these trials have shown any effects, and some large drug companies, including Pfizer, have abandoned this area of research altogether.

The continued failure of new drugs to make a difference has to be interpreted as evidence that the amyloid protein is not the cause of Alzheimer's disease. Some companies have changed their target to the tau protein. But again, drugs companies are assuming that a single is the cause of the disease.

Promising new avenues

Perhaps it is time to rethink the disease altogether. One approach is to look for genes that increase the risk of developing the disease. The problem with this approach is that there are surprisingly few of these genes, and they are rare. Alzheimer's does not appear to be driven by gene mutations, so this approach does not shed new light on the underlying processes.

Another option is to look at the risk factors for developing Alzheimer's. One of these is type 2 diabetes. Clearly, diabetes is very different from Alzheimer's disease, so what's the connection?

In diabetes, insulin becomes less effective at controlling blood sugar levels. But insulin does a lot more than just control blood sugar; it is a "growth factor". Neurons (brain cells) are very dependent on growth factors, and if they don't get enough, they die.

The loss of insulin's growth factor effects in the brain appear to make neurons vulnerable to stress and reduce the brain's ability to repair damage that accumulates over time. (Neurons live as long as we do, so there is a lot of time for damage to accrue.)

When looking at brain tissue taken from deceased Alzheimer's patients, researchers found that insulin lost its effectiveness as a growth factor, even in people who were not diabetic. This observation suggests that diabetes drugs might be an effective treatment for people with Alzheimer's. Some experiments showed impressive results in animal studies, and several clinical trials have started.

Testing these drugs in animal models of another neurodegenerative disorder, Parkinson's disease, also showed impressive effects, and two clinical trials in Parkinson's patients showed good protective effects. In one of the – a pilot study – the patients who received the diabetes drug did not get any worse for two years while the control group, who received a standard treatment for Parkinson's, deteriorated significantly. The other trial, a larger trial with a placebo control, confirmed this result and showed no deterioration in the drug group during the 12 months of study.

To see any protective effect in the brain in a clinical trial is completely new, and it supports the new theory that Alzheimer's and Parkinson's are caused, at least in part, by a lack of activity in the brain. These new theories bring a fresh view on how these diseases develop and increase the likelihood of developing a drug treatment that makes a difference.

Explore further: Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

Related Stories

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Diabetes drug 'significantly reverses memory loss' in mice with Alzheimer's

January 1, 2018
A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action.

Genetic technique reverses Alzheimer's processes in mice

February 15, 2018
Researchers in the US have used genetic techniques to slow the progression of Alzheimer's in mice that show features of the disease. The study, which centered around a protein called BACE1, was reported today in the Journal ...

Diabetes drug could influence brain activity in Alzheimer's

April 28, 2016
Researchers in Denmark have released findings from a small clinical trial of the diabetes drug liraglutide in people living with Alzheimer's disease.

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Sleep and Alzheimer's disease connection

October 17, 2017
How often do you get a good night's sleep? Centers for Disease Control and Prevention guidelines recommend adults get an average of at least seven hours of sleep a night. Dr. Ronald Petersen, a Mayo Clinic neurologist, says ...

Recommended for you

Scientists discover why some people with brain markers of Alzheimer's have no dementia

August 16, 2018
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the ...

Researchers identify new genes that may contribute to Alzheimer's disease

August 14, 2018
Researchers from Boston University School of Medicine, working with scientists across the nation on the Alzheimer's Disease Sequencing Project (ADSP), have discovered new genes that will further current understanding of the ...

Deaths from resident-to-resident incidents in dementia offers insights to inform policy

August 14, 2018
Analyzing the incidents between residents in dementia in long-term care homes may hold the key to reducing future fatalities among this vulnerable population, according to new research from the University of Minnesota School ...

Scientists propose a new lead for Alzheimer's research

August 14, 2018
A University of Adelaide-led team of scientists has suggested a potential link between iron in our cells and the rare gene mutations that cause Alzheimer's disease, which could provide new avenues for future research.

Eye conditions provide new lens screening for Alzheimer's disease

August 8, 2018
Alzheimer's disease is difficult to diagnose as well as treat, but researchers now have a promising new screening tool using the window to the brain: the eye.

Potential indicator for the early detection of dementias

August 7, 2018
Researchers at the University of Basel have discovered a factor that could support the early detection of neurodegenerative diseases such as Alzheimer's or Parkinson's. This cytokine is induced by cellular stress reactions ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

KenFine
not rated yet Jun 06, 2018
The connection between Alzheimer's disease and type 2 diabetes is that they are both the result of a chronically dysregulated immune response, driven by the transcription factor, NF-kB. This response is usually initiated to fight infection by pathogens which establish long term latency inside cells, but it can also occur in the absence of infection, due to a combination of genetic and environmental factors.

There is a higher incidence of infection by HSV-1 and chlamydia pneumoniae in AD brains, and T2DM is associated with a higher rate of infection by Hepatitis C, TB, E. coli and candida. The immune response attempts to resist infection by downregulating receptors used by pathogens to enter cells. This can take 3 forms, reduced expression, desensitization, and receptor blockade.

In T2DM, it is the insulin receptor which is downregulated, and in AD, it is the acetylcholine NACH receptor and noradrenaline receptors.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.